ANI Pharmaceuticals Reports Q3 Earnings Beat Driven by Strong Revenue Growth
ANI Pharmaceuticals (ANIP) reported third-quarter financial results that exceeded analyst expectations for both top-line revenue and bottom-line earnings per share. The company achieved a non-GAAP EPS of $2.70, surpassing estimates by $0.52, while total revenue rose 27.7% year-over-year to $290.8 million. A significant driver of this growth was the Purified Cortrophin® Gel product, which saw net revenues increase by 36.1% to $138.7 million. Despite the strong quarterly performance and earnings beat, the company has narrowed its total revenue outlook for fiscal year 2026.
Tickers: $ANIP